AI Summary
We reviewed 87 live results for trastuzumab biosimilar and narrowed them down to the 3 options that look most worth comparing first.
The strongest themes across this short list are Oncology and Monoclonal Antibodies.
Comparison Table
Recommended
Trastuzumab Biosimilar
Source: Biocon Biologics Philippines Inc.
Description
A biosimilar monoclonal antibody for the treatment of HER2-positive breast and gastric cancers, available in the Philippines since 2018.
Best for
HER2-positive breast cancer, gastric cancer treatment and oncology therapy
View Details
Rating
Herzuma (Trastuzumab)
Source: Celltrion Healthcare
Description
Herzuma is a biosimilar trastuzumab, a monoclonal antibody designed as a targeted oncology therapy for HER2-positive early breast cancer, metastatic breast cancer, and advanced gastric cancer. It is supplied as a powder for concentrate for solution for infusion in 150mg and 440mg vials.
Best for
HER2-positive breast cancer, metastatic gastric cancer patients, cost-effective targeted therapy and oncology infusion treatment
View Details
Rating
Trazimera (Trastuzumab)
Source: Pfizer Philippines Inc.
Description
Trazimera is a monoclonal antibody biosimilar for the treatment of HER2-positive breast and stomach cancers, receiving PH FDA approval in 2022.
Best for
HER2-positive breast cancer, stomach cancer and targeted oncology therapy
View Details
Rating
| Compare | Trastuzumab Biosimilar | Herzuma (Trastuzumab) | Trazimera (Trastuzumab) |
|---|---|---|---|
| Source | Biocon Biologics Philippines Inc. | Celltrion Healthcare | Pfizer Philippines Inc. |
| Description | A biosimilar monoclonal antibody for the treatment of HER2-positive breast and gastric cancers, available in the Philippines since 2018. | Herzuma is a biosimilar trastuzumab, a monoclonal antibody designed as a targeted oncology therapy for HER2-positive early breast cancer, metastatic breast cancer, and advanced gastric cancer. It is supplied as a powder for concentrate for solution for infusion in 150mg and 440mg vials. | Trazimera is a monoclonal antibody biosimilar for the treatment of HER2-positive breast and stomach cancers, receiving PH FDA approval in 2022. |
| Best for | HER2-positive breast cancer, gastric cancer treatment and oncology therapy | HER2-positive breast cancer, metastatic gastric cancer patients, cost-effective targeted therapy and oncology infusion treatment | HER2-positive breast cancer, stomach cancer and targeted oncology therapy |
| Tags | |||
| Action | View Details | View Details | View Details |
| Rating |
AI Recommendation
If you want the most balanced option to start with, I recommend:
"Trastuzumab Biosimilar from Biocon Biologics Philippines Inc.."
I picked this because This biosimilar provides a targeted oncology treatment for HER2-positive cancers with a proven local track record.
Share this search
Related Finds